Yabao Pharmaceutical Group Co Ltd Total Liabilities
Yabao Pharmaceutical Group Co Ltd total liabilities. Based on the latest financial reports, Yabao Pharmaceutical Group Co Ltd (600351) has total liabilities worth CN¥585.77 Million CNY (≈ $85.72 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check 600351 cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Yabao Pharmaceutical Group Co Ltd (1999–2024)
Total liabilities of Yabao Pharmaceutical Group Co Ltd from 1999 to 2024. This chart illustrates how Yabao Pharmaceutical Group Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore 600351 strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
Yabao Pharmaceutical Group Co Ltd Competitors by Total Liabilities
The table below lists competitors of Yabao Pharmaceutical Group Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Yixin Group Limited
F:1YX
|
Germany | €37.41 Billion |
|
Foshan Golden Milky Way Intelligent Equipment Co Ltd
SHE:300619
|
China | CN¥4.17 Billion |
|
Legacy Housing Corp
NASDAQ:LEGH
|
USA | $53.41 Million |
|
Atlantic China Welding Consumables Inc
SHG:600558
|
China | CN¥727.16 Million |
|
Beijing Qianjing Landscape Co
SHG:603778
|
China | CN¥2.17 Billion |
|
KSL Holdings Bhd
KLSE:5038
|
Malaysia | RM1.53 Billion |
|
Vital Energy Inc.
NYSE:VTLE
|
USA | $2.96 Billion |
Liability Composition Analysis (1999–2024)
This chart breaks down Yabao Pharmaceutical Group Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see total assets of Yabao Pharmaceutical Group Co Ltd.
Liquidity & Leverage Metrics
Yabao Pharmaceutical Group Co Ltd Total Liabilities Ratios Explained
Yabao Pharmaceutical Group Co Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.14 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.21 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.18 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Yabao Pharmaceutical Group Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Yabao Pharmaceutical Group Co Ltd (1999–2024)
The table below shows the annual total liabilities of Yabao Pharmaceutical Group Co Ltd from 1999 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥649.02 Million ≈ $94.97 Million |
-24.56% |
| 2023-12-31 | CN¥860.33 Million ≈ $125.89 Million |
-23.49% |
| 2022-12-31 | CN¥1.12 Billion ≈ $164.54 Million |
+1.02% |
| 2021-12-31 | CN¥1.11 Billion ≈ $162.88 Million |
-6.93% |
| 2020-12-31 | CN¥1.20 Billion ≈ $175.00 Million |
-24.70% |
| 2019-12-31 | CN¥1.59 Billion ≈ $232.41 Million |
-12.42% |
| 2018-12-31 | CN¥1.81 Billion ≈ $265.37 Million |
+24.71% |
| 2017-12-31 | CN¥1.45 Billion ≈ $212.79 Million |
-1.42% |
| 2016-12-31 | CN¥1.48 Billion ≈ $215.86 Million |
-6.27% |
| 2015-12-31 | CN¥1.57 Billion ≈ $230.30 Million |
+15.29% |
| 2014-12-31 | CN¥1.37 Billion ≈ $199.76 Million |
-9.36% |
| 2013-12-31 | CN¥1.51 Billion ≈ $220.39 Million |
+18.69% |
| 2012-12-31 | CN¥1.27 Billion ≈ $185.69 Million |
+14.16% |
| 2011-12-31 | CN¥1.11 Billion ≈ $162.66 Million |
-22.19% |
| 2010-12-31 | CN¥1.43 Billion ≈ $209.06 Million |
+8.99% |
| 2009-12-31 | CN¥1.31 Billion ≈ $191.82 Million |
+55.33% |
| 2008-12-31 | CN¥843.93 Million ≈ $123.49 Million |
+21.56% |
| 2007-12-31 | CN¥694.23 Million ≈ $101.59 Million |
+2.74% |
| 2006-12-31 | CN¥675.74 Million ≈ $98.88 Million |
-13.41% |
| 2005-12-31 | CN¥780.42 Million ≈ $114.20 Million |
+30.15% |
| 2004-12-31 | CN¥599.65 Million ≈ $87.75 Million |
+72.97% |
| 2003-12-31 | CN¥346.67 Million ≈ $50.73 Million |
+104.44% |
| 2002-12-31 | CN¥169.57 Million ≈ $24.81 Million |
-0.01% |
| 2001-12-31 | CN¥169.58 Million ≈ $24.82 Million |
+25.23% |
| 2000-12-31 | CN¥135.42 Million ≈ $19.82 Million |
+16.95% |
| 1999-12-31 | CN¥115.80 Million ≈ $16.94 Million |
-- |
About Yabao Pharmaceutical Group Co Ltd
Yabao Pharmaceutical Group Co., Ltd researches, develops, manufactures, and sells Chinese and Western medicines, and pharmaceutical packaging materials in China and internationally. It provides pediatric products, cardiovascular and cerebrovascular products, endocrine products, women's health products, patches, and general health products. Yabao Pharmaceutical Group Co., Ltd was founded in 1978 a… Read more